CAS 120210-48-2: Tenidap

Applications Tenidap is one of the nonsteroidal antiinflammatory drugs (NSAIDs). Tenidap is an NSAID that preferentially inhibits COX-1. Tenidap inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. References Moilanen, et al.: Eicosanoids, 1, 35 (1988), Kirchner, et al.: J. Pharmacol. Exp. Ther., 282, 1094 (1997), Liu, et al.: Eur. J. Pharmacol., 435, 153 (2002),

Tenidap

Tenidap (CP-66248) is a selective COX-1 and SLC26A3 inhibitor with anti-inflammatory, analgesic, and anti-rheumatic activities.

Tenidap is a synthetic anti-inflammatory drug, which is derived from the chemical modification of nonsteroidal anti-inflammatory drugs (NSAIDs). It functions as both a cyclooxygenase (COX) inhibitor and a modulator of cytokine production. This dual mode of action allows Tenidap to simultaneously reduce the synthesis of prostaglandins by inhibiting COX enzymes and suppress the production of pro-inflammatory cytokines like interleukin-1 and tumor necrosis factor. This makes it unique compared to traditional NSAIDs. Tenidap is primarily used in the treatment of inflammatory diseases such as rheumatoid arthritis and osteoarthritis. Its efficacy in reducing joint inflammation and alleviating pain while potentially mitigating the gastrointestinal side effects associated with standard NSAIDs has been a significant area of interest. Clinical investigations have focused on its dual-action mechanism to comprehend its therapeutic benefits and safety profile, emphasizing its potential in managing chronic inflammatory conditions where both pain suppression and cytokine modulation are critical.